
Nektar Therapeutics (NKTR) is back in focus after management moved its lead drug rezpegaldesleukin into multiple Phase III programs in atopic dermatitis and alopecia areata, alongside an early-stage trial in vitiligo.
For Nektar Therapeutics, the rezpegaldesleukin Phase III push and the latest earnings update land after a volatile stretch, with the share price down about 49% over the past 90 days and the 1 year total shareholder return falling 34%. At the same time, the 3 year total shareholder return is extremely strong relative to that, suggesting long term holders have seen large gains while shorter term momentum has clearly faded.
Scan beyond Nektar Therapeutics and compare this Phase III story with other high-potential candidates by checking the hand-picked 20 high quality undiscovered gems in similar early growth phases.
Nektar Therapeutics now trades at a steep discount to analyst targets after a sharp pullback. Is this simply a cautious reset focused on execution and timelines, or a genuine warning signal on valuation?
Nektar Therapeutics closed at $37.27 against an analyst consensus fair value of about $133.08, and the analyst consensus Narrative on Simply Wall St frames that gap around rezpegaldesleukin, long development timelines and a cash runway that extends into 2028.
The numbers indicate that investors currently treat the business cautiously, given limited revenue, ongoing losses and neutral analyst ratings, and that it is priced as if rezpegaldesleukin’s late stage pipeline and cash-funded runway to at least Q3 2028 may not fully translate into future share price gains.
See why 13 investors see Nektar Therapeutics as 72% undervalued.
Result: Fair Value of $133.08 (UNDERVALUED)
Still, the narrative around Nektar Therapeutics hinges on rezpegaldesleukin delivering successful Phase III outcomes and on ongoing losses not forcing dilution-heavy funding before 2028.
Find out about the key risks to this Nektar Therapeutics narrative.
Sentiment on Nektar Therapeutics is split, with clear concerns but also genuine optimism around rezpegaldesleukin. Move quickly, review the underlying data, and weigh both the 1 key reward and 3 important warning signs.
If you only stop at Nektar Therapeutics, you risk missing other opportunities that match your goals, risk tolerance, and time horizon on the Simply Wall St screener.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com